Nanostarch based nanoencapsulation of Mucuna pruriens extract and its evaluation as anti-parkinsonian drug
Parkinson's disease is a neurodegenerative disease caused by low dopamine levels in the brain. This study aims to obtain the optimum condition for M. pruriens extract nanoencapsulation in nano starch (NS-MPn) and nanostarch-maltodextrin (NS-MD-MPn), nanocapsules characteristics, and their poten...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier Ltd
2024
|
| Subjects: | |
| Online Access: | http://umpir.ump.edu.my/id/eprint/40087/1/Nanostarch%20based%20nanoencapsulation%20of%20Mucuna%20pruriens%20extract.pdf http://umpir.ump.edu.my/id/eprint/40087/ https://doi.org/10.1016/j.cscee.2023.100562 https://doi.org/10.1016/j.cscee.2023.100562 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Parkinson's disease is a neurodegenerative disease caused by low dopamine levels in the brain. This study aims to obtain the optimum condition for M. pruriens extract nanoencapsulation in nano starch (NS-MPn) and nanostarch-maltodextrin (NS-MD-MPn), nanocapsules characteristics, and their potential as anti-Parkinsonian drug. The nanoencapsulation process was carried out by ultrasonic method. FTIR, SEM, and TEM carried out the characterization of NS-MPn and NS-MD-MPn nanocapsules. Encapsulation efficiency was evaluated by UV-Vis spectroscopy. SEM and TEM characterization NS-MPn and NS-MD-MPn nanocapsules have non-spherical surface morphology, spherical in shape 234.98 and 90.85 nm, respectively. NS-MPn have 21.35% encapsulation efficiency, meanwhile, NS-MD-MPn has 30.02%. |
|---|